Literature DB >> 32025785

[Long and short QT syndromes : Emergency treatment and secondary prophylaxis].

N Horn1, N Rüb2, C Wolpert2.   

Abstract

Long QT syndrome (LQTS) is a rare inherited or acquired channelopathy associated with a relevant mortality if left untreated. Therapy can reduce the sudden cardiac death (SCD) rate significantly. Of 17 subtypes, LQTS1-3 are the most common. Clinical presentation ranges from asymptomatic patients to torsade de pointes (TdP) and SCD. Emergency therapy includes defibrillation, administration of magnesium, betablockers and temporary pacing and sedation. Secondary prevention is based on betablocker therapy and implantation of an implantable cardioverter-defibrillator (ICD), if appropriate. Short QT syndrome (SQTS) is a rare channelopathy that manifests as SCD in 34%. So far 250 cases with mutations in 8 genes have been reported. ICDs are the only reliable protection against SCD. Drug therapy is based on hydroquinidine. Further therapeutic options exist for certain subtypes of both diseases. Patients should be referred to specialized centers.

Entities:  

Keywords:  Channelopathy; Emergency treatment; Long-QT-Syndrome; Short-QT-Syndrome; Torsade de Pointes

Mesh:

Year:  2020        PMID: 32025785     DOI: 10.1007/s00399-020-00666-y

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  25 in total

1.  Idiopathic short QT interval: a new clinical syndrome?

Authors:  I Gussak; P Brugada; J Brugada; R S Wright; S L Kopecky; B R Chaitman; P Bjerregaard
Journal:  Cardiology       Date:  2000       Impact factor: 1.869

2.  Proposed diagnostic criteria for short QT syndrome are badly founded.

Authors:  Preben Bjerregaard
Journal:  J Am Coll Cardiol       Date:  2011-07-26       Impact factor: 24.094

3.  Efficacy of different beta-blockers in the treatment of long QT syndrome.

Authors:  Abeer Abu-Zeitone; Derick R Peterson; Bronislava Polonsky; Scott McNitt; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2014-09-30       Impact factor: 24.094

Review 4.  Quinidine-A legacy within the modern era of antiarrhythmic therapy.

Authors:  Laura Vitali Serdoz; Harald Rittger; Francesco Furlanello; Dirk Bastian
Journal:  Pharmacol Res       Date:  2019-04-23       Impact factor: 7.658

5.  Long-term follow-up of patients with short QT syndrome.

Authors:  Carla Giustetto; Rainer Schimpf; Andrea Mazzanti; Chiara Scrocco; Philippe Maury; Olli Anttonen; Vincent Probst; Jean-Jacques Blanc; Pascal Sbragia; Paola Dalmasso; Martin Borggrefe; Fiorenzo Gaita
Journal:  J Am Coll Cardiol       Date:  2011-08-02       Impact factor: 24.094

6.  Contemporary Outcomes in Patients With Long QT Syndrome.

Authors:  Ram K Rohatgi; Alan Sugrue; J Martijn Bos; Bryan C Cannon; Samuel J Asirvatham; Christopher Moir; Heidi J Owen; Katy M Bos; Teresa Kruisselbrink; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2017-07-25       Impact factor: 24.094

7.  Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery.

Authors:  Rainer Schimpf; Christian Wolpert; Francesca Bianchi; Carla Giustetto; Florenzo Gaita; Urs Bauersfeld; Martin Borggrefe
Journal:  J Cardiovasc Electrophysiol       Date:  2003-12

8.  Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery.

Authors:  Christopher A Collura; Jonathan N Johnson; Christopher Moir; Michael J Ackerman
Journal:  Heart Rhythm       Date:  2009-03-19       Impact factor: 6.343

Review 9.  Recent Advances in Short QT Syndrome.

Authors:  Oscar Campuzano; Georgia Sarquella-Brugada; Sergi Cesar; Elena Arbelo; Josep Brugada; Ramon Brugada
Journal:  Front Cardiovasc Med       Date:  2018-10-29

Review 10.  Emerging therapeutic targets in the short QT syndrome.

Authors:  Jules C Hancox; Dominic G Whittaker; Chunyun Du; A Graham Stuart; Henggui Zhang
Journal:  Expert Opin Ther Targets       Date:  2018-05       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.